Ignite Creation Date:
2024-07-17 @ 10:41 AM
Last Modification Date:
2024-10-26 @ 3:33 PM
Study NCT ID:
NCT06485466
Status:
RECRUITING
Last Update Posted:
2024-07-03
First Post:
2024-06-22
Brief Title:
TACE Plus Camrelizumab and Apatinib for Unresectable Hepatocellular Carcinoma
Sponsor:
Guohui Xu
Organization:
Sichuan Cancer Hospital and Research Institute
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Unresectable Hepatocellular Carcinoma |
| Transarterial Chemoembolization |
| Camrelizumab |
| Apatinib |
Keywords: